Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04445987 · ClinicalTrials.gov registry record · Phase 2
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
A Phase 2 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 408
- Enrollment target
NCT04445987 is a Phase 2 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 408 participants.
The verdict
NCT04445987, a Phase 2 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 408 participants
- Enrollment target
Study Summary
This is an open-label, long-term safety study of roflumilast ARQ-154 foam 0.3% in subjects with seborrheic dermatitis involving up to 20% total Body Surface Area (BSA). Study was applied topically once daily for 52 weeks. Cohort 1 subjects are rollover subjects from study ARQ-154-203 (NCT04091646) and were rolled into treatment in the current study without interruption. Cohort 2 includes participants from ARQ-154-203 who began treatment in the current study after a gap from completing treatment in the prior study.
Interventions
- DRUG ARQ-154
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2020-06-12 |
| Est. Completion | 2022-11-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04445987
The ClinicalTrials.gov registry entry for NCT04445987 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARQ-154 is the first listed.
NCT04445987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04445987 about?
NCT04445987 is a clinical study titled "Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis". This is an open-label, long-term safety study of roflumilast ARQ-154 foam 0.3% in subjects with seborrheic dermatitis involving up to 20% total Body Surface Area (BSA). Study was applied topically once daily for 52 weeks. Cohort 1 subjects are rollover subjects from study ARQ-154-203 (NCT04091646) a...
What is the current status of trial NCT04445987?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 408 participants. The study started on 2020-06-12. Estimated completion is 2022-11-19.
What interventions are being tested in trial NCT04445987?
The interventions under investigation include: ARQ-154 (DRUG).
Who is sponsoring clinical trial NCT04445987?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.